The company's first test for the detection of bladder cancer could be available in Europe within a couple of months.
Israeli cancer detection company Nucleix has raised $3 million from Morris Kahn's Aurum Ventures MKI, OrbiMed Israel Partners, and Zohar Zisapel, OrbiMed and Zohar Zisapel invested in the startup's first $5.5 million financing round and the company has also raised $3 million from private investors.
Nucleix is involved in the relatively new research field of epigenetics (a situation in which identical genes express themselves in different ways) in order to detect different types of cancers. Cancer cells are different from healthy cells with chemical patterns, which are added on to or not added on to their genes. Nucleix has developed a method that can read the epigene patterns in different cells. The company's first test for the detection of bladder cancer could be available in Europe within a couple of months.
Nucleix was founded in 2008 by CEO Elon Ganor a former CEO of voice-over-IP pioneer VocalTec, and Weizmann Institute graduates VR research Dr. Danny Frumkin, and VP development Dr. Adam Wasserstrom. Dr Opher Shapira is president and COO.
Published by Globes [online], Israel business news - www.globes-online.com - on May 23, 2016
© Copyright of Globes Publisher Itonut (1983) Ltd. 2016